Table 6 Clinical, functional, and laboratory data presented as the difference between results at baseline and at 6 months, according to allergy status
From: Real-life experience with benralizumab during 6 months
Variables | Non-atopic (n = 28) | Atopic (n = 14) | p |
|---|---|---|---|
Subjective improvement*, n (%) | 25 (96) | 13 (93) | 1 |
Corticosteroid-dependent at 6 months, n (%) | 6 (21.4) | 2 (14.3) | 0.225 |
ACT*, md (IR) | 8 (3) | 5 (4) | 0.061 |
No. of ED visits at 6 months; md (IR) | 2 (8) | 1 (8) | 1 |
Post-BD FEV1, mL*; md (IR) | 307 (295) | 379 (343) | 0.465 |
Post-BD FEV1, %*; md (IR) | 11 (7) | 14 (15) | 0.541 |
FeNO, ppb*; md (IR) | 38 (29) | 25 (30) | 0.158 |
Blood eosinophil count, cells/ÎĽL*; md (IR) | 751 (234) | 725 (374) | 0.650 |